DACT3-DVL1 Interaction-Mediated Canonical WNT Signaling Regulates Non-Small Cell Lung Cancer Progression and

Jingrong Zheng1, Yudie Lu1, Mengdi Yang1

  • 1Department of Pathology, the First Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, Liaoning, People's Republic of China.

Insights

Disheveled binding antagonist of β-catenin 3 (DACT3) inhibits non-small cell lung cancer (NSCLC) progression by interacting with disheveled 1 (DVL1). This interaction suppresses WNT/β-catenin signaling, reducing metastasis and improving cisplatin resistance in NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Disheveled binding antagonist of β-catenin 3 (DACT3) negatively regulates WNT signaling.
  • Disheveled 1 (DVL1) dysregulation is implicated in cancer progression.
  • The roles of DVL1 and DACT3 in non-small cell lung cancer (NSCLC) remain unclear.

Purpose of the Study:

  • To investigate the expression and interaction of DACT3 and DVL1 in NSCLC.
  • To elucidate the mechanism by which DACT3 influences DVL1-mediated WNT signaling in NSCLC.
  • To determine the therapeutic potential of the DACT3-DVL1 interaction in NSCLC treatment.

Main Methods:

  • Immunohistochemical analysis of DACT3 and DVL1 expression in NSCLC tissues.
  • Cell-based assays including Western blot, luciferase activity, immunofluorescence, and co-immunoprecipitation.
  • Transfection of DACT3/DVL1 cDNA and siRNA-DACT3 in NSCLC cells to assess WNT pathway activation and biological behavior.

Main Results:

  • Reduced DACT3 expression correlated with lymphatic metastasis and poor NSCLC prognosis.
  • A negative correlation was observed between DACT3 and DVL1 expression levels.
  • DACT3 inhibited NSCLC cell invasion, proliferation, migration, tumorigenesis, and cisplatin resistance by suppressing WNT/β-catenin signaling via DVL1 interaction.
  • DACT3-DVL1 interaction reduced GSK-3β and β-catenin phosphorylation, inhibiting β-catenin nuclear translocation and downstream target gene expression.

Conclusions:

  • DACT3 acts as a tumor suppressor in NSCLC by inhibiting DVL1-induced WNT/β-catenin signaling.
  • The DACT3-DVL1 interaction offers a potential therapeutic strategy for NSCLC, enhancing chemosensitivity to cisplatin.